N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects

• Main Author: Keizo Kanasaki
• Format: Article
• Language: English
• Published: Wiley 2020-05-01
• Series: Journal of Diabetes Investigation
• Subjects: Angiotensin‐converting enzyme; Endothelial–mesenchymal transition; Fibroblast growth factor
• Online Access: https://doi.org/10.1111/jdi.13219

Abstract N‐acetyl‐seryl‐aspartyl‐lysyl‐proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ‐protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, AcSDKP has been recognized as valuable antifibrotic peptide. The antifibrotic mechanism of AcSDKP is not yet clear; we have established that AcSDKP could target endothelial–mesenchymal transition program through the induction of the endothelial fibroblast growth factor receptor signaling pathway. Also, recent reports suggested the clinical significance of AcSDKP. The aim of this review was to update recent advances of the mechanistic action of AcSDKP and discuss translational research aspects.